Table 1.
Demographic and clinical characteristics of the studied cohort.
| Total | Repaired | Unrepaired | p values | |
|---|---|---|---|---|
| N (%) | 49 | 38 (78%) | 11 (22%) | |
| Age (years) | 76.1 ± 7.0 | 76.3 ± 7.0 | 75.9 ± 8.9 | 0.89 |
| Sex (M/F) | 19/30 | 17/21 | 2/9 | 0.08 |
| Eye (R/L) | 23/26 | 18/20 | 5/6 | 0.70 |
| Follow-up (months) | 16.3 ± 3.0 | 16.5 ± 3.2 | 16.0 ± 2.6 | 0.63 |
| BCVA (LogMAR) | ||||
| At RPE tear | 0.54 ± 0.27 | 0.52 ± 0.26 | 0.62 ± 0.33 | 0.37 |
| At follow-up | 0.66 ± 0.37 | 0.59 ± 0.32 | 0.87 ± 0.33 | 0.04 |
| No. of injections | 7.4 ± 3.4 | 7.4 ± 3.6 | 7.2 ± 2.9 | 0.60 |
| SMH at baseline (%) | 21 (43%) | 16 (42%) | 5 (45%) | 0.76 |
| Tear onset | ||||
| Early (%) | 33 (67%) | 25 (66%) | 8 (73%) | 0.40 |
| Late (%) | 16 (33%) | 13 (34%) | 3 (27%) | |
| Tear grade | ||||
| Grade 1 | 4 (8%) | 4 (11%) | 0 (0%) | 0.93 |
| Grade 2 | 9 (18%) | 7 (18%) | 2 (18%) | |
| Grade 3 | 19 (39%) | 13 (34%) | 6 (55%) | |
| Grade 4 | 17 (35%) | 14 (37%) | 3 (27%) | |
| MNV type | ||||
| Type 1 (occult) | 37 (76%) | 30 (79%) | 7 (64%) | 0.21 |
| Type 2 (classic) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Type 3 (RAP) | 12 (24%) | 8 (21%) | 4 (36%) | |
| Anti-VEGF used | ||||
| Bevacizumab | 15 (31%) | 11 | 4 | 0.86 |
| Ranibizumab | 21 (43%) | 17 | 4 | |
| Aflibercept | 13 (26%) | 10 | 3 | |
Legend: N, number; BCVA, best-corrected visual acuity; SMH, sub-macular hemorrhage; MNV, macular neovascularization; RAP, retinal angiomatous proliferation; VEGF, vascular endothelial growth factor.